Valerio Therapeutics signs deal to buy Etherna Immunotherapies for €30 million enterprise value
Reuters2026/08/24 06:00- Valerio Therapeutics agreed to acquire Etherna Immunotherapies in a deal valuing Etherna at EUR 30 million enterprise value.
- Consideration includes cash funded by a EUR 40.25 million PIPE, with remaining payment in Valerio shares via in-kind Etherna share contributions.
- Valerio issued 68,220,333 new shares at EUR 0.59 each; settlement-delivery is expected Aug. 26, 2026.
- Shareholder approval for the in-kind contribution leg is targeted for around Oct. 6, 2026, backed by undertakings exceeding 70%.
- Transaction adds Etherna’s mRNA and LNP platforms and GMP manufacturing, supporting Valerio’s push into targeted RNA delivery beyond the liver.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
JPMorgan: Tesla (TSLA.US) Robotaxi revenue may reach $320 billions by 2035, with nearly 98% coming from its own fleet
JPMorgan analyst Rajat Gupta released a research report last week, estimating that by 2035, Tesla's Robotaxi revenue will reach approximately $320 billion, with nearly $314 billion coming from Tesla's own and operated fleet, rather than from the owner-operated "Tesla Network."
FDA approves Telix brain cancer imaging drug Pixclara for glioma PET scans
Charles Hoskinson Says AI Has Destroyed The Old Crypto Growth Metric
Kvika appoints Jón Birgir Jónsson as CEO, effective Dec. 1
Crypto prices
More
